Oral fluid nanosensor test (OFNASET) with advanced electrochemical-based molecular analysis platform
Oral fluid nanosensor test (OFNASET) with advanced electrochemical-based molecular analysis platform
复制标题
DOI：
10.1196/annals.1384.005
复制
发表时间：
2007-01-01
期刊：
影响因子：
--
通讯作者：
Wong, David
中科院分区：
文献类型：
--
作者：
Gau, Vincent;Wong, David
高影响疾病，包括癌症，心血管疾病和神经系统疾病，在没有实验室检测补充临床评估的情况下诊断具有挑战性。即使有实验室工具，明确的诊断往往仍然难以捉摸。缺乏三个关键要素是实现临床诊断测试潜力的障碍：（1）明确的疾病相关蛋白和遗传标记，（2）简单廉价的采样方法，受试者的不适最小，（3）准确和定量诊断平台。我们的目标是开发和验证需求（3）的解决方案，并开发一个便携式系统。要求（1）和（2）将分别通过利用新型和高度特异性的口腔癌唾液蛋白质组学和基因组生物标志物以及使用唾液作为选择的生物流体来解决。口腔液纳米传感器测试（OFNASET）技术平台结合了尖端技术，如自组装单分子层（SAM），生物纳米技术，循环酶扩增和微流体，以及几种成熟的技术，包括微注射成型，基于杂交的检测和分子纯化。OFNASET的预期用途是用于口腔癌唾液生物标志物的床旁多重检测。我们已经证明，两种唾液蛋白质组学生物标志物（硫氧还蛋白和IL-8）和四种唾液mRNA生物标志物（SAT，ODZ，IL-8和IL-Ib）的组合可以以高特异性和灵敏度检测口腔癌。我们的初步研究显示了令人信服的结果。我们将IL-8抗原、探针溶液、洗涤液、酶溶液、洗涤液和介体溶液的系列稀释液依次递送到容纳在原型盒中的传感器反应室中，并在高于阴性对照的50 pg/mL下表现出强信号分离。
High-impact diseases, including cancer, cardiovascular disease, and neurological disease, are challenging to diagnose without supplementing clinical evaluation with laboratory testing. Even with laboratory tools, definitive diagnosis often remains elusive. The lack of three crucial elements presents a road block to achieving the potential of clinical diagnostic tests: (1) definitive disease-associated protein and genetic markers, (2) easy and inexpensive sampling methods with minimal discomfort for the subject, and (3) an accurate and quantitative diagnostic platform. Our aim is to develop and validate a solution for requirement (3) and also to develop a portable system. Requirements (1) and (2) will be addressed through the utilization of novel and highly specific oral cancer saliva proteomic and genomic biomarkers and the use of saliva as the biofluid of choice, respectively. The Oral Fluid NanoSensor Test (OFNASET) technology platform combines cutting-edge technologies, such as self-assembled monolayers (SAM), bionanotechnology, cyclic enzymatic amplification, and microfluidics, with several well-established techniques including microinjection molding, hybridization-based detection, and molecular purification. The intended use of the OFNASET is for the point of care multiplex detection of salivary biomarkers for oral cancer. We have demonstrated that the combination of two salivary proteomic biomarkers (thioredoxin and IL-8) and four salivary mRNA biomarkers (SAT, ODZ, IL-8, and IL-Ib) can detect oral cancer with high specificity and sensitivity. Our preliminary studies have shown compelling results. We sequentially delivered a serial dilution of IL-8 antigen, probe solution, wash, enzyme solution, wash, and mediator solution to sensor reaction chambers housed in a prototype cartridge and demonstrated strong signal separation at 50 pg/mL above a negative control.